

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/949,572 entitled "Free Floating Cryostat Sections for Immunoelectron Microscopy," filed September 10, 2001. Foreign rights are also available (PCT/US01/28340). The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** This invention relates to the field of histology and immuno-histology using immunoelectron microscopy. More specifically, this invention relates to the field of free-floating cryostat sections for use in light and electron microscopy to bridge the gap between these two viewing mediums.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19709 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Heterologous Protection Induced by Immunization With Invaplex Vaccine**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 10/150,814 entitled "Heterologous Protection Induced by Immunization with Invaplex Vaccine," filed May 17, 2002. Foreign rights (PCT/US02/16029) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** In this application is described a composition, Invaplex, derived from a gram negative bacteria for use in generating an immune response in a subject against one or more heterologous species or strains of gram-negative bacteria.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19710 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Microfluidized Leishmania Lysate and Methods of Making and Using Thereof**

**AGENCY:** Department of the Army, DOD.  
**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/975,020 entitled "Microfluidized Leishmania Lysate and Methods of Making and Using Thereof," filed October 12, 2001. Foreign rights (PCT/US01/31894) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** This invention relates generally to microfluidized *Leishmania* lysate

preparations. In particular, the present invention relates to microfluidized *Leishmania* lysate preparations for assays and immunogenic compositions.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19715 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins**

**AGENCY:** Department of the Army, DOD.  
**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the related U.S. patent applications concerning "Specific Inhibitors and therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins" listed below. The United States Government, as represented by the Secretary of the Army, has rights in these inventions. Foreign rights are also available.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 1702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, bh at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** The following patents are available for licensing:

(1) *U.S. Patent Application No.:* 09/570,022.  
*Filed:* May 12, 2000.

*Title:* Previns as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

(2) *U.S. Patent Application No.:* 09/570,023.  
*Filed:* May 12, 2000.

*Title:* Buforin I as a Specific Inhibitor and Therapeutic Agent for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used to inhibit the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/12909) are also available.

(3) *U.S. Patent Application No.:* 09/979,101.

*Filed:* November 19, 2001.

*Title:* Prexins as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

**Luz D. Ortiz,**

*Army Federal Register Liaison Officer.*

[FR Doc. 02-19712 Filed 8-2-02; 8:45 am]

**BILLING CODE 3910-08-M**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### Prospective Grant of a Partially Exclusive License

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice of intent.

**SUMMARY:** In accordance with the provisions of 15 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(I), U.S. Army Soldier and Biological Chemical Command (SBCCOM) hereby gives notice that it is contemplating the grant of a partially exclusive license in the United States to practice the inventions embodied in U.S. Patents 5,884,418, issued March 23, 1999, entitled, "Process and System for Impregnating Garments with Insect Repellent" and 5,930,909, issued August 3, 1999, entitled, "System for Impregnating Garments with Insect Repellent" to Spinnerin Dye, LLC having a place of business in South Hackensack, New Jersey and Buzz Off Insect Shield, LLC having a place of business in Greensboro, North Carolina.

**FOR FURTHER INFORMATION CONTACT:** Mr. Robert Rosenkrans at U.S. Army Soldier and Biological Chemical Command, Kansas Street, Natick, MA 01760, Phone: (508) 233-4928 or E-mail: [Robert.Rosenkrans@natick.army.mil](mailto:Robert.Rosenkrans@natick.army.mil).

**SUPPLEMENTARY INFORMATION:** The prospective partially exclusive licenses will be royalty bearing and will comply

with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive licenses may be granted, unless SBCCOM receives written evidence and argument to establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Written objections along with supporting evidence, if any, are to be filed on or before August 20, 2002.

**Luz D. Ortiz,**

*Army Federal Register Liaison Officer.*

[FR Doc. 02-19703 Filed 8-2-02; 8:45 am]

**BILLING CODE 3710-08-M**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### Privacy Act of 1974; System of Records

**AGENCY:** Department of the Army, DOD.

**ACTION:** Notice to Alter a System of Records.

**SUMMARY:** The Department of the Army is altering a system of records notice in its existing inventory of record systems subject to the Privacy Act of 1974, (5 U.S.C. 552a), as amended. The alteration adds four routine uses to the existing system of records.

**DATES:** This proposed action would be effective without further notice on September 4, 2002 unless comments are received which result in a contrary determination.

**ADDRESSES:** Records Management Division, U.S. Army Records Management and Declassification Agency, ATTN: TAPC-PDD-RP, Stop 5603, 6000 6th Street, Ft. Belvoir, VA 22060-5603.

**FOR FURTHER INFORMATION CONTACT:** Ms. Janice Thornton at (703) 806-4390 or DSN 656-4390 or Ms. Christie King at (703) 806-3711 or DSN 656-3711.

**SUPPLEMENTARY INFORMATION:** The Department of the Army systems of records notices subject to the Privacy Act of 1974, (5 U.S.C. 552a), as amended, have been published in the **Federal Register** and are available from the address above.

The proposed system report, as required by 5 U.S.C. 552a(r) of the Privacy Act of 1974, as amended, was submitted on July 22, 2002, to the House Committee on Government Reform, the Senate Committee on Governmental Affairs, and the Office of Management and Budget (OMB) pursuant to paragraph 4c of Appendix I to OMB Circular No. A-130, 'Federal Agency Responsibilities for Maintaining

Records About Individuals,' dated February 8, 1996 (February 20, 1996, 61 FR 6427).

Dated: July 30, 2002.

**Patricia L. Toppings,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

#### A0195-2b USACIDC

##### SYSTEM NAME:

Criminal Investigation and Crime Laboratory Files (December 8, 2000, 65 FR 77002).

##### CHANGES:

\* \* \* \* \*

##### CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:

Add 'witnessing' to entry.

##### CATEGORIES OF RECORDS IN THE SYSTEM:

Add 'and criminal intelligence reports', 'suspects', 'polygraph reports', and 'and intelligence' to entry.

\* \* \* \* \*

##### PURPOSE(S):

Delete entry and replace with 'To conduct criminal investigations, crime prevention and criminal intelligence activities; to accomplish management studies involving the analysis, compilation of statistics, quality control, etc., to ensure that completed investigations are legally sufficient and result in overall improvement in techniques, training and professionalism. Includes personnel security, internal security, criminal, and other law enforcement matters, all of which are essential to the effective operation of the Department of the Army.

The records in this system are used for the following purposes: Suitability for access or continued access to classified information; suitability for promotion, employment, or assignment; suitability for access to military installations or industrial firms engaged in government projects/contracts; suitability for awards or similar benefits; use in current law enforcement investigation or program of any type including applicants; use in judicial or adjudicative proceedings including litigation or in accordance with a court order; advising higher authorities and Army commands of the important developments impacting on security, good order or discipline; reporting of statistical data to Army commands and higher authority; input into the Defense Security Service managed Defense Clearance and Investigations Index (DCII) database under system notice V5-02.'